Alpha 2.0
Login Register
» Articles » PMID: 2183714

Comparative in Vitro Activities of 20 Fluoroquinolones Against Mycobacterium Leprae

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1990 Feb 1
PMID 2183714
Citations 20
Authors
S G Franzblau
K E White
Affiliations
Soon will be listed here.
Abstract

The in vitro activities of 20 fluoroquinolones against Mycobacterium leprae were evaluated by using the BACTEC 460 system. M. leprae was incubated in BACTEC 12B medium at 33 degrees C under reduced oxygen for 2 to 3 weeks in the presence of fluoroquinolones at 0.31 to 5 micrograms/ml. Activity was determined by a reduction in 14CO2 evolution compared with that of drug-free controls. Of the commercially available agents, ofloxacin was most active, while enoxacin and norfloxacin were inactive. However, a number of newer fluoroquinolones (AT-4140, OPC-17100, OPC-17066, PD-117596, PD-124816, PD-127391, and WIN-57273), all containing a cyclopropyl group at R-1 and, with the exception of WIN-57273, either a halogen or methyl group at R-8, were more active than ofloxacin in vitro. Further in vivo evaluations of these agents should help determine their potential for use against leprosy.

Citing Articles

Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models.

Saxena S, Spaink H, Forn-Cuni G Biology (Basel). 2021; 10(2).

PMID: 33573039 PMC: 7911849. DOI: 10.3390/biology10020096.

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

da Silva Cruz R, Buhrer-Sekula S, Penna M, Penna G, Talhari S An Bras Dermatol. 2018; 92(6):761-773.

PMID: 29364430 PMC: 5786388. DOI: 10.1590/abd1806-4841.20176724.

Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis.

Darby C, Ingolfsson H, Jiang X, Shen C, Sun M, Zhao N PLoS One. 2013; 8(7):e68942.

PMID: 23935911 PMC: 3728290. DOI: 10.1371/journal.pone.0068942.

Synthesis of N-substituted 2-[(1E)-alkenyl]-4-(1H)-quinolone derivatives as antimycobacterial agents against non-tubercular mycobacteria.

Wube A, Bucar F, Hochfellner C, Blunder M, Bauer R, Hufner A Eur J Med Chem. 2011; 46(6):2091-101.

PMID: 21429630 PMC: 3096000. DOI: 10.1016/j.ejmech.2011.02.062.

Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.

Matrat S, Petrella S, Cambau E, Sougakoff W, Jarlier V, Aubry A Antimicrob Agents Chemother. 2007; 51(5):1643-8.

PMID: 17325221 PMC: 1855561. DOI: 10.1128/AAC.01282-06.

References
1.
Hardy D, SWANSON R, Hensey D, Ramer N, BOWER R, Hanson C . Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987; 31(11):1768-74. PMC: 175036. DOI: 10.1128/AAC.31.11.1768. View
2.
PATTYN S . Activity of ofloxacin and pefloxacin against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 1987; 31(4):671-2. PMC: 174807. DOI: 10.1128/AAC.31.4.671. View
3.
Franzblau S, OSullivan J . Structure-activity relationships of selected phenazines against Mycobacterium leprae in vitro. Antimicrob Agents Chemother. 1988; 32(10):1583-5. PMC: 175923. DOI: 10.1128/AAC.32.10.1583. View
4.
Franzblau S, Hastings R . In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother. 1988; 32(12):1758-62. PMC: 176013. DOI: 10.1128/AAC.32.12.1758. View
5.
Leysen D, Haemers A, PATTYN S . Mycobacteria and the new quinolones. Antimicrob Agents Chemother. 1989; 33(1):1-5. PMC: 171410. DOI: 10.1128/AAC.33.1.1. View